The results of a preclinical study across multiple models of acute myeloid leukemia found that the investigational hypomethylating agent, NTX-301 remained effective in treatment-resistant AML and TP53-mutant AML through activating the Hippo pathway. The post Novel Epigenetic Therapy Targets Treatment-Resistant and TP53-Mutant AML appeared first on GEN – Genetic Engineering and Biotechnology News.
You may also like
EC approves Erbitux combination for first‑line...
FDA approves Leqembi Iqlik subcutaneous initiation...
AstraZeneca agrees on $1.5bn deal with Dizal...
Cherry appoints Peter Henshaw as new Managing Director
Cellares and Sonoma Biotherapeutics Agree to Automate...
Genome-Scale CRISPRi Atlas Maps Gene Function Across...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.